I decided to finalize my bearish thesis on Gossamer Bio (GOSS) and put it all in one article.
Gossamer Bio, Inc. is San Diego based biotech start-up. The lead drug candidate of the company, GB001, is being evaluated at Phase-2b for the treatment of moderate-to-severe eosinophilic asthma.
The company must first show the effectiveness of its drug candidate, and then, if it succeeds, prove the advantages of its medicine over other competing products on the market. I am skeptical of this probability. Next, I will explain the reasons for my skepticism.
Before